Alan R. Stewart - 09 Jul 2025 Form 4 Insider Report for Calidi Biotherapeutics, Inc. (CLDI)

Reporting relationship: Director
Issuer ticker: CLDI
Reported as of: 09 Jul 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 15 Jul 2025, 20:42:57 UTC
Prior SEC filing: 04 Mar 2025
Next SEC filing: 21 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Andrew Jackson, Attorney-in-fact

Key filing fact

Alan R. Stewart filed Form 4 for Calidi Biotherapeutics, Inc. (CLDI) on 15 Jul 2025.

Key facts

This page summarizes Alan R. Stewart's Form 4 filing for Calidi Biotherapeutics, Inc. (CLDI).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 15 Jul 2025, 20:42.

Change

Previous filing in this sequence was filed on 04 Mar 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001705492 Primary reporting owner

Stewart Alan R.

Relationship: Director
Address: C/O CALIDI BIOTHERAPEUTICS, INC., 4475 EXECUTIVE DRIVE, SUITE 200, SAN DIEGO,
Signature: /s/ Andrew Jackson, Attorney-in-fact
Signature date: 15 Jul 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CLDI transaction Derivative

Non-Qualified Stock Options (right to buy)

Award

Transaction value: $0
Shares: +137,078
Change %
Price: $0.000000
Shares after: 137,078
Date: 09 Jul 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 137,078
Exercise price: $0.7000
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

On July 15, 2025, the Reporting Person was issued a non-qualified stock option to purchase 137,078 shares of common stock (the "Options") at an exercise price of $0.70 per share (equal to the closing price on the grant date, July 9, 2025) and shall vest, and become exercisable, in 1/12th per month installments over one year commencing on the grant date. The stock options were granted pursuant to the Issuer's non-employee director compensation policy and issued under the Issuer's 2023 Equity Incentive Plan.

SEC remarks

Exhibit 24 - Power of Attorney (previously filed as Exhibit 24 to Form 4 dated July 2, 2024.)